DOCSLIB.ORG
Explore
Sign Up
Log In
Upload
Search
Home
» Tags
» Relacorilant
Relacorilant
Efficacy and Safety of the Selective Glucocorticoid Receptor Modulator
Recurrence After Pituitary Surgery in Adult Cushing's Disease: a Systematic Review on Diagnosis and Treatment
European Medicines Agency Recommends Orphan Drug Designation for Relacorilant to Treat Patients with Cushing’S Syndrome
Hypokalemia Associated with Mifepristone Use in the Treatment of Cushing’S Syndrome
Study Protocol Cort125134-451
Rxoutlook® 3Rd Quarter 2020
Glucocorticoid Receptor Antagonism Promotes Apoptosis in Solid Tumor Cells
Public Summary of Opinion on Orphan Designation Relacorilant for the Treatment of Cushing’S Syndrome
Lääkeaineiden Yleisnimet (INN-Nimet) 31.12.2019
Fixing the Broken Clock in Adrenal Disorders: Focus on Glucocorticoids and Chronotherapy
Annexes to the 2019 Annual Report of the European Medicines Agency
PDF Download
Summer 2018 Cushing’S Newsletter
0830 TH 7 ORIC Pharmaceuticals, Inc V2.Pptx
Clinical Trial Announcement
Medical Treatments in Cushing's Syndrome
An Overview of the Current and Recent Clinical Trials
Clinical Management of Patients with Cushing Syndrome Treated with Mifepristone: Consensus Recommendations David R
Top View
Slides 2 of 2
INN-Nimet 1 20.8.2019 a Abacavir Abacavirum Abakaviiri